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Editorial on the Research Topic
Minding Glial Cells in the Novel Understandings of Mental Illness
During the last few decades, it has been assumed that dysfunctions of neurons and neuronal
networks including synaptic abnormalities and consecutive disturbances of neurotransmitters
are the main and sole causes of psychiatric disorders. Recent neuroscience has revealed various
previously unknown roles of glial cells such as astrocytes, oligodendrocytes, and microglia
as modulators of neurotransmission. These glial cells have proved to continuously contact
with neurons/synapses, and have been shown to play important roles in brain development,
homeostasis, and various brain functions. Beyond the classic neuronal doctrine of neuropsychiatry,
accumulating evidence has suggested that abnormalities and disturbances of the crosstalk between
neurons and glial cells may induce mental dysfunction and be a risk factor for the manifestation of
psychiatric disorders. However, these mechanisms have yet to be well-understood.
This research topic of “the Frontiers in Cellular Neuroscience” has focused on the most recent
developments and ideas in the study of glial cells (astrocytes, oligodendrocytes, and microglia)
targeting psychiatric disorders such as schizophrenia, mood disorders, and autism. Here, we
publish more than 20 articles including original research, review, perspective, and commentary.
While all of the articles are focused on psychiatric disorders, a variety of methods/approaches have
been employed from molecular, cellular, and pharmacological approaches using in vitro/in vivo
experimental methods to translational approaches using human tissues.
Human postmortem research using brain tissues of patients with psychiatric disorders is
one of the most important research approaches in biological psychiatry. In this research topic,
Bernstein et al. reported a reduced density of glutamine synthetase immunoreactive astrocytes in
different cortical areas in major depression but not in bipolar I disorder. Falkai et al. revealed an
interaction between a decrease of oligodendrocyte and interneuron density in the hippocampus of
schizophrenia patients and discussed the association of oligodendrocyte number with cognitive
deficits, proposing that a decreased number of oligodendrocytes in the anterior, and entire
hippocampus may be involved in cognitive deficits by impairing the connectivity of this structure
in schizophrenia.
On the other hand, various novel approaches of brain imaging techniques have been developed
to reveal glial dysfunctions in living patients with psychiatric disorders (Kato et al., 2013a).
Peripheral blood markers are also suggested to be useful biomarkers of psychiatric disorders. For
example, S100B has been considered as a glial marker protein, particular to oligodendrocytes
and astrocytes. It passes the blood brain barrier and is detectable in peripheral blood. In this
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research topic, Schumberg et al. reported that serum S100B
is related to illness duration and clinical symptoms in
schizophrenia by a meta-regression analysis. Furthermore,
combination analysis between brain imaging data and blood
data is becoming one of the most highlighted approaches
in psychiatry. Milleit et al. conducted an association analysis
between brain imaging data of voxel based morphometry
(VBM) and serum S100B concentrations in unmedicated patients
with schizophrenia and healthy volunteers, and revealed that
serum S100B protein is specifically related to white matter
changes in patients with schizophrenia. This report suggests
the involvement of S100B in an ongoing and dynamic process
associated with structural brain changes and brain connectivity
in schizophrenia.
As mentioned above, peripheral blood markers including
components/materials of serum, plasma, and genes are possible
useful biomarkers of psychiatric disorders. In addition,
blood cells themselves have also been highlighted as possible
biomarkers. Microglia and peripheral monocytes (monocytic
cells) are both of mesodermal origin. Takahashi et al. discussed
this linkage focusing on the activation ofmicroglia and peripheral
monocytes to understand the pathophysiology of psychiatric
disorders. Ohgidani et al. introduced a novel translational tool
for neuropsychiatric disorders, called “induced microglia-like
(iMG) cells,” which can be produced within 2 weeks from fresh
human monocytes by adding only two cytokines (GM-CSF and
IL-34). They have recently reported on the suitability of the
iMG cells to study and understand microglial pathophysiology
in patients with schizophrenia and bipolar disorder (Sato-Kasai
et al., 2016; Ohgidani et al., 2017). Alternatively, human induced
pluripotent stem (iPS) cells- and embryonic stem (ES)-oriented
microglia-like cells (termed pMGLs) may also prove to be
suitable tools (Muffat et al., 2016). We believe that both the
generation of iMG cells and pMGLs will provide a strong
method to reveal the potential contribution of microglial cells in
psychiatric disorders in more detail.
In spite of great advances in human research tools as
shown above, animal models are still thought to be essential
for psychiatric research. Epidemiological studies suggest that
prenatal exposure to bacterial and viral infection is an important
environmental risk factor for schizophrenia. The maternal
immune activation (MIA) animal model is used to study how
an insult directed at the maternal host can have adverse effects
on the fetus, leading to behavioral and neurochemical changes
later in life. In this research topic, de Souza et al. observed an
upregulation of astroglial markers (S100B and GFAP) in a MIA
model of schizophrenia by LPS in Wistar rats; the brain-regional
expression pattern was sex-dependent. Smolders et al. reported
that MIA evoked by polyinosinic:polycytidylic acid (polyI:C)
does not evoke microglial cell activation in the embryo. This
report suggests that the behavioral and neurological alterations in
offspring cannot be related to the alteration of the activation state
of embryonic microglial cells. Their in vitro studies also indicated
that microglia cannot be directly activated by poly (I:C) or IL-
6 exposure. However, recent studies in other research groups
indicate that there is an increase in microglial density in different
brain regions in the adult poly (I:C)MIA offspring (postnatal and
adult age) (Juckel et al., 2011;Manitz et al., 2013). As commentary
responding to Smolders et al., Bernstein et al. suggested the
role of astrocytic activation in the brains of MIA offspring.
Further investigations are needed to understand the relevance of
microglial and astrocytic activation in each developmental stage
of the MIA models.
On the other hand, the Cuprizone-treatment rodent model,
one of the classical models of multiple sclerosis (MS), is now
regarded as a useful model of schizophrenia (Xiao et al.,
2008), showing a series of dysfunctions of glial cells such as
microglia, astrocytes, and oligodendrocytes. Wang et al. reported
that quetiapine inhibits microglial activation by neutralizing
abnormal STIM1-mediated intercellular calcium homeostasis
and promoting myelin repair in a cuprizone-induced mouse
model of demyelination. Interestingly, Gentile et al. proposed
the merit of utilizing the behavioral and neuro-glial studies with
experimental autoimmune encephalomyelitis (EAE)—the most
famous animal model of MS in order to explore the role of
microglia in mood disorders.
This special issue also contains two mice model studies
focusing on anxiety and glial cells. Zimmer et al. demonstrated
that long-term administration of memantine (a NMDAR
antagonist) induced anxiety-like behaviors, and decreased
glutamate uptake activity in both the frontoparietal cortex
and hippocampus without altering the immunocontents of
the astroglial glutamate transporters GLT-1 and GLAST. Chen
et al. reported that impairment of oligodendroglia maturation
leads to aberrantly increased cortical glutamate and anxiety-like
behaviors in juvenile mice.
High throughput technology of genome analysis, especially
genome-wide association study (GWAS), has shown various
candidate genes of psychiatric disorders such as schizophrenia
and bipolar disorder (Psychiatric GWAS Consortium Bipolar
DisorderWorking Group, 2011; Ripke et al., 2013; Schizophrenia
Working Group of the Psychiatric Genomics, 2014). Apart
from genome analyses, proteome and metabolome analyses are
expected to reveal unknown biological aspects of psychiatric
disorders (Kaddurah-Daouk andKrishnan, 2009; Domenici et al.,
2010; Setoyama et al., 2016). In this research topic, Davalieva
et al. reviewed the recent advances of proteomic research
in schizophrenia. Three original research articles applying
the proteomic analysis of glial cells with a pharmacological
intervention are also included in this topic. Guest et al. reported
that MK-801 treatment affects glycolysis in oligodendrocytes
more than in astrocytes and neuronal cells. Cassoli et al.
compared effects of MK-801 and the antipsychotic drug
clozapine on the proteome of cultured oligodendrocytes. In
addition, focusing in a hypothesis-driven study on energy
metabolism, Steiner et al. compared the typical antipsychotic
drug haloperidol with the atypical antipsychotic compound
clozapine; only the latter promoted glycolysis and myelin lipid
synthesis in cultured oligodendrocytes. These data suggest that
psychotropic drugs, originally developed for the modulation of
neurons and/or synaptic neurotransmission, are also acting on
astrocytes and oligodendrocytes. Similarly, recent in vitro studies
using rodent microglial cells have revealed that psychotropic
drugs, especially antipsychotics and antidepressants may also
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directly modulate microglial cells (Kato et al., 2011, 2013b),
however the underlying signal transduction mechanisms have
not been well clarified. In this research topic, Mizoguchi et al.
proposed that microglial intracellular Ca2+ signaling may be an
important target of antipsychotic actions. On the other hand,
epigenetic mechanisms may be important disease modifiers. In
line with this idea, Chen et al. introduced the recent topic of DNA
methylation in glial cells for further research of schizophrenia.
In this research topic, we have included several review papers
proposing interesting theories and hypotheses linking psychiatric
disorders with dysfunctions of glial cells: Yamamuro et al.
introduced potential primary roles of glial cells in the underlying
mechanisms of psychiatric disorders. Petrelli et al. discussed
the possible link between autism spectrum disorders and glial
cells especially astrocytes and microglia. Koyama introduced
functional alterations of astrocytes in mental disorders, and
proposed pharmacological modulation of astrocytes as a novel
drug target. Noda depicted a possible role of glial cells in the
relationship between thyroid dysfunction and mental disorders.
And finally, Stokes et al. discussed the recent evidence for
an involvement of microglial and/or astrocytic P2X7 in the
pathophysiology of depressive disorders.
We are very pleased to publish a broad spectrum of papers
focusing on glial cells in the field of psychiatry utilizing multi-
dimensional approaches. We believe that further investigations
to clarify the correlation between glial cells and psychiatric
disorders will contribute to a novel understanding of the
pathophysiology of mental illnesses and the development of
effective treatment strategies.
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